Selecta Biosciences(NASDAQ:SELB) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 27, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $2.930M. Analysts estimated a revenue of $7.090M. The revenues were -58.67% below the estimates. Earnings per share were $-0.77. The reported EPS was below estimates by -541.67%. Analysts had estimated an EPS of $-0.12.
Selecta Biosciences (SELB) made into the market gainers list on Fridays trading session with the shares advancing 10.56% or 1.15 points. Due to strong positive momentum, the stock ended at $12.04, which is also near the day’s high of $12.37. The stock began the session at $11 and the volume stood at 35,111 shares. The 52-week high of the shares is $27.9995 and the 52 week low is $10.26. The company has a current market capitalization of $219 M and it has 1,81,90,180 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jan 30, 2017, Lloyd P. Johnston (COO AND SVP, R&D) sold 15,000 shares at $14.06 per share price.Also, On Dec 23, 2016, David Abraham (CCO, Gen.Counsel, Corp.Sec.) sold 14,844 shares at $18.00 per share price.On Dec 21, 2016, Peter Keller (Chief Business Officer) sold 4,723 shares at $18.58 per share price, according to the Form-4 filing with the securities and exchange commission.